Clinical Trial Update: Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial [Phase 2]

View source ↗

Summary

A Phase II multicenter trial evaluating a modified FOLFIRINOX regimen in gemcitabine-refractory pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Yonsei University | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED